#ASH16: Pfiz­er of­fers a thumbs-up on OS da­ta from PhII blood can­cer study of glas­deg­ib

Pfiz­er came up with some solid­ly pos­i­tive Phase II da­ta for a new drug that’s de­signed to throw a mon­key wrench in­to the bi­ol­o­gy dri­ving the hedge­hog path­way in acute myeloid leukemia.

In­ves­ti­ga­tors said that glas­deg­ib, an oral SMO in­hibitor ini­tial­ly cod­ed PF-04449913, sig­nif­i­cant­ly in­creased the over­all sur­vival of a group of pa­tients tak­ing the drug in com­bi­na­tion with low-dose cy­tara­bine (LDAC) com­pared to LDAC alone.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters